ArticleMycopathologia2022
A Chronic Autochthonous Fifth Clade Case of Candida auris Otomycosis in Iran.
Article in Mycopathologia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- In Vitro Activity and In Vivo Efficacy in a Murine Model of Rezafungin, Anidulafungin, Caspofungin, and Micafungin Against the Fifth Clade ofJournal of fungi (Basel, Switzerland) · 2026Article
- Article
- Candida auris: a multidimensional focus on its identification, epidemiology, pathogenesis, and therapeutic options.Archives of microbiology · 2026Review
- UnderstandingJournal of medical microbiology · 2026Review
- Pathogenicity Evaluation on Fluconazole-Resistant Candida auris Clade V in Murine Model.Mycopathologia · 2025Article
- Molecular Identification ofAdvanced biomedical research · 2025Article
- A simple and sensitive test forJournal of clinical microbiology · 2024Article
- Emergence of the novel sixthMicrobiology spectrum · 2024Article
- Yeast species in the respiratory samples of COVID-19 patients; molecular tracking ofFrontiers in cellular and infection microbiology · 2024Article
- An Autochthonous SusceptibleJournal of fungi (Basel, Switzerland) · 2023Article
- Candida auris: a global pathogen that has taken root in ColombiaBiomedica : revista del Instituto Nacional de Salud · 2023Article
- Development of a Novel Method for the Clinical Visualization and Rapid Identification of Multidrug-Resistant Candida auris.Microbiology spectrum · 2023Article
- Development and Validation of TaqMan Chemistry Probe-Based Rapid Assay for the Detection of Echinocandin-Resistance in Candida auris.Journal of clinical microbiology · 2023Article
- Candida auris Infection in a Meningococcal Septicemia Survivor, Poland.Mycopathologia · 2023Article
- Strategies to Prevent Transmission ofCurrent fungal infection reports · 2023Review
- Confirmation of fifthEmerging microbes & infections · 2022Article
- Utility of CHROMagar™ Candida Plus for presumptive identification of Candida auris from surveillance samples.Mycopathologia · 2022Article
- Population genomic analyses reveal evidence for limited recombination in the superbugComputational and structural biotechnology journal · 2022Article
- Diagnostic Allele-Specific PCR for the Identification ofJournal of fungi (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Candida auris, a multidrug-resistant nosocomial pathogen, has emerged globally with high morbidity and mortality among immunocompromised individuals and COVID19 hospitalized patients. Five major clades of C. auris have been previously described. The fifth clade is exclusively found in Iran where C. auris isolates are genetically distinct from other clades by > 200,000 single-nucleotide polymorphisms. The origin of C. auris remains unclear, and limited clinical data are available at present regarding clade V infection or colonization. Herein, another case of otomycosis in Iran caused by an isolate of C. auris belonging to the fifth clade is reported. Genotyping revealed that the obtained C. auris isolate from Isfahan clustered with earlier clade V isolates from Babol, cities around 600 km separated, which indicates that C. auris clade V is established in Iran. C. auris is thought to exist more commonly in Iran, given that limited diagnostic capacity in the country has probably curbed the identification of more C. auris cases. Therefore, surveillance of the environment, patients and healthcare facilities in different geographical regions in Iran is urgently required.
Indexed as
Identifiers
34855102What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.